The Synaptic Dysfunction of Neurodegenerative Diseases (SynDegen) consortium is an assembly of leading academic research group and specialized enterprises (SMEs) come together to provide training for PhD students through the support of the EU Horizon 2020 Marie Skłodowska-Curie grant. The centers in the consortium represent internationally top-ranking teams and leading EU neuroscientists, who are not only recognized international specialists in their fields but are also embedded into scientific and medical structures of excellence in their respective countries of the EU.

Neurodegenerative diseases (NDDs) are a major public health concern as the numbers of those afflicted with the most common of these diseases, Alzheimer’s, Parkinson’s and Huntington’s diseases, continue to rise around the world. Increasing evidence has pointed to synapses, the contact points of neurons in the brain, as vulnerable sites of attack in neurodegenerative diseases. Aggregation-prone proteins linked to these diseases, such as α-synuclein, Aβ/APP and tau, normally localize and with disease abnormally aggregate at synapses. Moreover, synaptic activity promotes secretion of these disease-linked proteins that appear to spread through the brain via synapses.

SynDegen offers a unique training opportunity for talented early stage researchers with interest in NDDs, providing high-quality training with access to cutting-edge technology in innovative and creative research environments. The SynDegen ITN emphasizes the interaction between academic laboratories and the biotechnological industry and aims to provide a broad training in the conceptual framework and the full range of scientific techniques and approaches that are required to perform translational medical research from basic research to drug discovery.

SynDegen currently has 12 Early-Stage Researchers enrolled as PhD students, working with projects in the field of neurodegenerative diseases.

 

 

EU Horizon 2020 Marie Sklodowska-Curie Actions

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 721802.